Global GLP-1 Drug Manufacturing & Supply Chain Market Strategic Research Report 2026-2031

The global GLP-1 drug manufacturing and supply chain market represents one of the most capacity-constrained segments in the pharmaceutical industry today, with manufacturing capacity value expanding at nearly double the rate of end-market drug revenue. As per this report, the global GLP-1 manufacturing market which was worth USD 45.0 billion in 2025 is expected to grow at a CAGR of 26.0% between 2026 and 2031, reaching approximately USD 180.0 billion by 2031 -- growth driven almost entirely by real, confirmed capacity constraints rather than demand uncertainty.

Both Eli Lilly and Novo Nordisk, the two dominant GLP-1 innovators, have publicly cited manufacturing capacity -- not commercial, regulatory, or demand factors -- as the binding constraint on patient access through 2023 and 2024. This report finds that peptide synthesis complexity, requiring specialized fermentation and peptide-manufacturing infrastructure that has taken years to build out, remains the single most important structural constraint on the category's growth.

A significant, quantified reshoring wave is reshaping the contract development and manufacturing organization (CDMO) landscape. Of an estimated USD 24.86 billion in total 2025 global CDMO capacity investment specific to this category, approximately USD 18.48 billion -- nearly three-quarters -- was directed to US and non-China facilities, a real, confirmed shift driven by sponsor risk diversification following documented Chinese CDMO supply disruptions.

This report profiles seven key manufacturing and supply chain participants including Eli Lilly, Novo Nordisk, Novo Holdings (via Catalent), Samsung Biologics, Lonza, WuXi Biologics, and Biocon Biologics, with detailed capacity analysis, regional manufacturing geography, and forward-looking supply chain risk assessment through 2031.

Scope of Global GLP-1 Drug Manufacturing & Supply Chain Market Strategic Research Report 2026-2031

• This report provides forecast data by value (USD Billion) for the global GLP-1 manufacturing and supply chain market, with 2025 as the base year and forecasting to 2031.
• This report provides segmentation by manufacturing type (peptide synthesis, fermentation, fill-finish, device/delivery) and by manufacturing geography.
• This report identifies key growth drivers and inhibitors affecting GLP-1 manufacturing capacity expansion.
• This report provides company profiles including Company Overview, Manufacturing Capacity, Financial Performance, and SWOT Analysis for key manufacturing and CDMO participants.
• This report provides Porter's Five Forces, PESTLE, and SWOT analysis for the global GLP-1 manufacturing market.
• This report identifies key future trends in GLP-1 manufacturing capacity build-out through 2031.

Who can use the Global GLP-1 Drug Manufacturing & Supply Chain Market Research Report?

This research report is ideal for people who wish to gain a thorough understanding of the GLP-1 manufacturing and supply chain market. Some of the intended users for this report are:

• C-level executives and Company Directors in pharmaceutical manufacturing and CDMO companies
• Supply chain and manufacturing strategy professionals
• Industry consultants and Management consultants
• Investment managers, Financial professionals, and Venture Capitalists
• Bank Managers, M&A Managers, and Auditors
• Anyone operating in the GLP-1 manufacturing and CDMO value chain.